Search results for "MCRC"

showing 9 items of 19 documents

How we treat metastatic colorectal cancer.

2020

Colorectal cancer is the second leading cause of cancer-related death worldwide. About 20% of patients suffer from metastatic disease at diagnosis, while about one-third of patients treated with curative intent relapsed. In these patients, an accurate staging allows to plan a treatment strategy within a multidisciplinary team in order to achieve predefined goals. Patient's clinical features, tumour characteristics and molecular profile (RAS/BRAF and microsatellite instability (MSI) status) should be considered during the treatment choice. Combination of chemotherapy (fluoropyrimidines, oxaliplatin and irinotecan) plus biological agents (antiepidermal growth factor receptor or antiangiogenic…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentDiseaseReviewlcsh:RC254-282chemistry.chemical_compoundmCRCreviewInternal medicineRegorafenibhowitreatMedicineHumansmetastaticcolorectalcancer1506Neoplasm MetastasisUracilTipiracilChemotherapybusiness.industryMicrosatellite instabilitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOxaliplatinCRCIrinotecanOxaliplatinOncologychemistrymCRCQuality of LifebusinessColorectal Neoplasmsmedicine.drugESMO open
researchProduct

Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experi…

2017

Background/Aim: To evaluate the role of densitometric criterion using the Choi Criteria in the assessment of the response to antiangiogenic treatments of metastatic colorectal cancer (mCRC) compared to the RECIST criteria. Patients and Methods: Fifty-four patients (mean age=50.6 years ) affected by advanced colorectal cancer and with hepatic and possibly peritoneal and pulmonary metastases, that can be treated with bevacizumab, were prospectively evaluated by computerized tomography (CT) scan. Metastases were also evaluated by CT in onedimensional form according to RECIST. Results: Results show that in 58% of analyzed cases, stable disease according to RECIST coincided with stable disease a…

OncologyMalemedicine.medical_specialtyCancer ResearchBevacizumabDensitometric criteriaColorectal cancerAntiangiogenic therapyAngiogenesis InhibitorsColorectal NeoplasmAdvanced colorectal cancerStable DiseaseChoi CriteriaInternal medicinePartial responseMultidetector Computed TomographymedicineHumansDemographybusiness.industryDisease progressionLiver NeoplasmsMean ageGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeRECISTOncologyItalyLiver NeoplasmCHOIFemaleMetastatic colorectal cancer (mCRC)businessColorectal Neoplasmsmedicine.drugAngiogenesis InhibitorHumanDensitometryAnticancer research
researchProduct

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

2015

BACKGROUND: Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.METHODS: Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using…

Oncologymedicine.medical_specialtyDisease-Free SurvivalCholangiocarcinoma03 medical and health sciencesAdvanced diseaseCisplatin and gemcitabine0302 clinical medicineInternal medicinemedicineJournal ArticleHumansProgression-free survivalProportional Hazards ModelsPerformance statusReceiver operating characteristicManchester Cancer Research Centrebusiness.industryProportional hazards modelResearch Support Non-U.S. Gov'tResearchInstitutes_Networks_Beacons/mcrcHazard ratioArea under the curveCancerHematologymedicine.diseasePrognosisConfidence intervalSurgeryTreatment OutcomeOncologyBile Duct NeoplasmsROC Curve030220 oncology & carcinogenesisABC-02Multivariate AnalysisBiliary tract cancer030211 gastroenterology & hepatologybusinessPerformance statusPrognostic modelMeta-Analysis
researchProduct

Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-instit…

2021

INTRODUCTION: There have been significant developments in colorectal cancer (CRC) research over the last few years, with the introduction of new agents that have been prolonged median overall survival of metastatic colorectal cancer (mCRC). These therapies have improved patient outcomes; however, despite significant progress in strategies for cancer treatment, their use is limited by development of resistant mechanism. Almost 30% of patients with refractory mCRC will remain good candidates for further treatment. Regorafenib and TAS-102 are novel antitumor agents for patients with refractory mCRC. However, it is unclear which patients may derive a survival benefit from these drugs in real-li…

Oncologymedicine.medical_specialtyPyrrolidinesReal Life Clinical dataPyridinesColorectal cancerTrifluridinechemistry.chemical_compoundRefractoryInternal medicineRegorafenibmedicineHumansUracilRetrospective Studiesbusiness.industryPhenylurea CompoundsGastroenterologyRetrospective cohort studymedicine.diseaseTAS-102Disease controlCancer treatmentClinical trialDrug CombinationsOncologychemistrymCRCCohortchemorefractoryregorafenibColorectal NeoplasmsbusinessThymine
researchProduct

Shape coexistence in Hg-178

2019

Lifetime measurements of excited states in Hg-178 have been performed using the Rh-103(Kr-78, p2n) reaction at a beam energy of 354 MeV. The recoil-decay tagging (RDT) technique was applied to select the Hg-178 nuclei and associate the prompt gamma rays with the correlated characteristic ground-state alpha decay. Lifetimes of the four lowest yrast states of Hg-178 have been determined using the recoil distance Doppler-shift (RDDS) method. The experimental data are compared to theoretical predictions with focus on shape coexistence. The results confirm the shift of the deformed prolate structures to higher lying states but also indicate their increasing deformation with decreasing neutron nu…

PhysicsGEManchester Cancer Research Centre3106010308 nuclear & particles physicsYrastResearchInstitutes_Networks_Beacons/mcrcNuclear structureProlate spheroidNuclear Structure01 natural sciences114 Physical sciencesLIFETIMESPLUNGERRecoilSTATESExcited stateNeutron number0103 physical sciencesMERCURYAtomic physics010306 general physicsNuclear ExperimentBeam energy
researchProduct

Lifetime measurements in 166Re : Collective versus magnetic rotation

2016

WOS: 000371740600004

PhysicsManchester Cancer Research Centreta114010308 nuclear & particles physicsResearchInstitutes_Networks_Beacons/mcrcMagnetic rotationRouthianNuclear TheoryOrder (ring theory)Semiclassical physicsState (functional analysis)rhenium01 natural sciencesNuclear shapeRecoilExcited state0103 physical scienceslifetimesAtomic physics010306 general physicsexcited statesPhysical Review C
researchProduct

TPEN: A Triple-foil differential Plunger for lifetime measurements of excited states in Exotic Nuclei

2019

Abstract A Triple-foil differential Plunger for Exotic Nuclei (TPEN) has been developed to measure the lifetimes of excited states in nuclei with small production cross-sections. TPEN utilises one target foil and two degrader foils to make differential lifetime measurements: directly determining the decay function and its derivative at a single plunger distance setting. The direct measurement of the decay function and its derivative removes the requirement to measure γ -ray intensities at several target-to-degrader distances, thereby reducing the beam-time required relative to a conventional plunger with a single-degrader foil. This paper describes the commissioning of TPEN in the lifetime …

PlungerPhysicsNuclear and High Energy PhysicsDDCMManchester Cancer Research Centreta114ResearchInstitutes_Networks_Beacons/mcrctutkimuslaitteet156Dyplungerexcited-state lifetimestriple-foil plungerRDDSDecay functionExcited stateAtomic physicsydinfysiikkaInstrumentationFOIL method
researchProduct

Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the International Society for Extracellular Vesicl…

2018

The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines fo…

ectosomeectosomes; exosomes; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardization; Histology; Cell Biology[SDV]Life Sciences [q-bio]minimal information requirementsectosomes; exosomes; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardizationsize-exclusionectosomesMedicine and Health SciencesCELL-DERIVED MICROPARTICLESFIELD-FLOW FRACTIONATIONguidelinesrequirementscirculatingComputingMilieux_MISCELLANEOUSmicroparticlesManchester Cancer Research Centrelcsh:Cytologyextracellular vesicles; exosomes; ectosomes; microvesicles; minimal information requirements; guidelines; standardization; microparticles; rigor; reproducibilityPROSTATE-CANCERmicroparticleCell interactionmicrovesiclechromatographyPosition Paperextracellular vesiclesguidelineLife Sciences & Biomedicinemicrovesiclesectosomes exosomes extracellular vesicles guidelines microparticles microvesicles minimal information requirements reproducibility rigor standardizationMEMBRANE-VESICLESHistologyFETAL BOVINEEctosomes ; Exosomes ; Extracellular Vesicles ; Guidelines ; Microparticles ; Microvesicles ; Minimal Information Requirements ; Reproducibility ; Rigor ; StandardizationCIRCULATING MICROPARTICLES[SDV.BC]Life Sciences [q-bio]/Cellular Biologyexosomesddc:570exosomeSURFACE-PLASMON RESONANCEddc:610lcsh:QH573-671BiologyreproducibilitystandardizationInteracció cel·lularScience & TechnologyResearchInstitutes_Networks_Beacons/mcrcCell BiologyrigorCell membranesHUMAN URINARY EXOSOMESPREANALYTICAL PARAMETERSminimal information requirementSIZE-EXCLUSION CHROMATOGRAPHY1182 Biochemistry cell and molecular biologyextracellular vesicleHuman medicineMembranes cel·lulars
researchProduct

Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database.

2020

Purpose: To survey risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) practice and advice regarding hormone replacement therapy (HRT) in women with Lynch syndrome. Methods: We conducted a survey in 31 contributing centers from the Prospective Lynch Syndrome Database (PLSD), which incorporates 18 countries worldwide. The survey covered local policies for risk-reducing hysterectomy and BSO in Lynch syndrome, the timing when these measures are offered, the involvement of stakeholders and advice regarding HRT. Results: Risk-reducing hysterectomy and BSO are offered to path_MLH1 and path_MSH2 carriers in 20/21 (95%) contributing centers, to path_MSH6 carriers in 19/21 (91%) and…

medicine.medical_treatmentCàncer d'ovarilcsh:Medicinecomputer.software_genreleikkaushoitoCOLORECTAL-CANCER0302 clinical medicineHormone replacement therapy (female-to-male)munasarjasyöpäMalalties hereditàriesGynecological surgery030219 obstetrics & reproductive medicineManchester Cancer Research CentreDatabaseBrief ReportGeneral MedicineLynch syndrome3. Good healthESTROGENkohdunrungon syöpägynekologiset syövätovarian cancer030220 oncology & carcinogenesisendometrial cancerhormonihoitosyöpätauditHEALTHGenetic disordersGenetic counseling3122 Cancersehkäisevä lääketiede03 medical and health sciencesmedicinerisk-reducing surgeryMedical prescriptionLynchin oireyhtymäperinnölliset tauditHysterectomybusiness.industryResearchInstitutes_Networks_Beacons/mcrcHORMONE REPLACEMENT THERAPYEndometrial cancerlcsh:RInternational survey3126 Surgery anesthesiology intensive care radiologymedicine.diseaseLynch syndromeCàncer d'endometririsk reducing surgerybusinesscomputer
researchProduct